PNH drug iptacopan under safety microscope: infection risk tracked
NCT ID NCT06903234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors about 200 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking iptacopan (Fabhalta). Researchers will use registry data to count infections caused by certain bacteria. The goal is to better understand the real-world safety of this medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iptacopan (Fabhalta)
- What this could lead to
- If successful, this study will provide real-world safety data on iptacopan for PNH, helping doctors understand infection risks.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results depend on registry data quality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOGLOBINURIA, PAROXYSMAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Basel, Switzerland